Sodium–glucose co-transporter 2 (SGLT-2) inhibitors contribute to an increased risk of genital tract infections, according to a study. Furthermore, higher doses of dapagliflozin appear to be associated with a higher risk of urinary tract infection.
A 14-day course of reverse hybrid therapy is as effective as bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infection, although the former is associated with fewer adverse events, according to the results of a trial.
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Antiviral treatment for colonic cytomegalovirus (CMV) infection significantly improves short- and long-term surgery-free survival in patients with ulcerative colitis (UC), according to the results of a small-scale study.
Less than half of patients in this study have met the criteria for severe Clostridium difficile infection (CDI). Furthermore, almost half of providers for those with severe infection and longer duration of antibiotic therapy are less likely to adhere to the institutional guideline.
A US study suggests that expanding HIV screening to reduce undiagnosed infections and increasing access to care and treatment to achieve viral suppression are important to lessen HIV transmission. It is also imperative that prevention methods, such as condoms and pre-exposure prophylaxis, be easily accessed, particularly among young men who have sex with men (MSM) and MSM of colour.
Hepatitis C virus (HCV) patients receiving direct-acting antiviral treatment are at lower risk of developing liver cancer compared with those on interferon-based treatment or receiving no treatment, a study suggests.
Cessation of antiviral therapy in patients with immune-tolerant chronic hepatitis B (HBV) leads to rapid virological relapse as well as clinical relapse, according to a new study. Moreover, hepatitis B e antigen (HBeAg) seroconversion is rare whether or not patients reinitiated treatment.
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.